These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31700629)

  • 1. Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience.
    Maconi G; Mezzina N; Landi S; Grillo S; Bezzio C; Bosani M; Pastorelli L; Dell'Era A; Chibbar R; Carmagnola S; Molteni P; Cassinotti A; Massari A; Ardizzone S
    United European Gastroenterol J; 2019 Nov; 7(9):1164-1170. PubMed ID: 31700629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®
    Danese S; Hart A; Dignass A; Fiorino G; Louis E; Bonovas S; D'Haens G; Dotan I; Rogler G; Paridaens K; Peyrin-Biroulet L
    United European Gastroenterol J; 2019 Nov; 7(9):1171-1182. PubMed ID: 31700630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.
    Bonovas S; Nikolopoulos GK; Piovani D; González-Lorenzo M; Pantavou K; Lytras T; Peyrin-Biroulet L; Danese S
    Br J Clin Pharmacol; 2019 Oct; 85(10):2244-2254. PubMed ID: 31269287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
    Sandborn WJ; Travis S; Moro L; Jones R; Gautille T; Bagin R; Huang M; Yeung P; Ballard ED
    Gastroenterology; 2012 Nov; 143(5):1218-1226.e2. PubMed ID: 22892337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands.
    Gherardi A; Roze S; Kuijvenhoven J; Ghatnekar O; Yip Sonderegger YL
    J Med Econ; 2018 Sep; 21(9):869-877. PubMed ID: 29857775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis.
    Hoy SM
    Drugs; 2015 May; 75(8):879-86. PubMed ID: 25920500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
    Bosworth BP; Sandborn WJ; Rubin DT; Harper JR
    Inflamm Bowel Dis; 2016 Aug; 22(8):1881-6. PubMed ID: 27416045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile.
    Danese S; Bonovas S; Peyrin-Biroulet L
    J Crohns Colitis; 2017 Jul; 11(7):767-768. PubMed ID: 28333203
    [No Abstract]   [Full Text] [Related]  

  • 9. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.
    Danese S; Siegel CA; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2014 May; 39(10):1095-103. PubMed ID: 24641622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis.
    Lichtenstein GR; Travis S; Danese S; D'Haens G; Moro L; Jones R; Huang M; Ballard ED; Bagin R; Hardiman Y; Collazo R; Sandborn WJ
    J Crohns Colitis; 2015 Sep; 9(9):738-46. PubMed ID: 26094251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
    Sandborn WJ; Danese S; D'Haens G; Moro L; Jones R; Bagin R; Huang M; David Ballard E; Masure J; Travis S
    Aliment Pharmacol Ther; 2015 Mar; 41(5):409-18. PubMed ID: 25588902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
    Travis SP; Danese S; Kupcinskas L; Alexeeva O; D'Haens G; Gibson PR; Moro L; Jones R; Ballard ED; Masure J; Rossini M; Sandborn WJ
    Gut; 2014 Mar; 63(3):433-41. PubMed ID: 23436336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis.
    D'Haens GR; Kovács A; Vergauwe P; Nagy F; Molnár T; Bouhnik Y; Weiss W; Brunner H; Lavergne-Slove A; Binelli D; Di Stefano AF; Marteau P
    J Crohns Colitis; 2010 Jun; 4(2):153-60. PubMed ID: 21122499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
    Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
    Rubin DT; Cohen RD; Sandborn WJ; Lichtenstein GR; Axler J; Riddell RH; Zhu C; Barrett AC; Bortey E; Forbes WP
    J Crohns Colitis; 2017 Jul; 11(7):785-791. PubMed ID: 28333362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A practical guide to the management of distal ulcerative colitis.
    Ardizzone S; Bianchi Porro G
    Drugs; 1998 Apr; 55(4):519-42. PubMed ID: 9561342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis.
    Lichtenstein GR
    Dig Dis Sci; 2016 Feb; 61(2):358-70. PubMed ID: 26541989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
    Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S
    Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
    Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
    Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A safety evaluation of budesonide MMX for the treatment of ulcerative colitis.
    Bezzio C; Festa S; Zerboni G; Papi C; Manes G; Saibeni S
    Expert Opin Drug Saf; 2018 Apr; 17(4):437-444. PubMed ID: 29473429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.